Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2020

01-06-2020 | Computed Tomography | Case Report

A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control

Authors: Kazutaka Iijima, Mitsuharu Oozeki, Kaori Ikeda, Hiroyuki Honda, Hajime Ishibashi, Masaharu Yamaoka, Shinji Fujieda, Hitoaki Saitoh, Mitsuhide Goto, Masahiro Araki, Kenji Amagai

Published in: Clinical Journal of Gastroenterology | Issue 3/2020

Login to get access

Abstract

Small bowel adenocarcinomas are rare. There is no definite consensus as to whether they should be treated in a manner similar to gastric or to colon cancer. We report the case of a young woman with a primary jejunal adenocarcinoma, bilateral ovary metastases, and peritoneal dissemination. First- and second-line chemotherapy for the gastric cancer failed. She was then treated with the immune checkpoint inhibitor nivolumab and had temporary improvement in her condition. To the best of our knowledge, this is the first case wherein nivolumab has been used to treat small bowel adenocarcinoma.
Literature
1.
Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev. 1998;7:243–51.
2.
Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973–1990. Int J Epidemiol. 1996;25:722–8.CrossRef
3.
Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.CrossRef
4.
Shenoy S. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol. 2016;8:509–19.CrossRef
5.
Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46:97–104.CrossRef
6.
Syngal S, Brand RE, Church JM, American College of Gastroenterology, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRef
7.
Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119(06):1447–53.CrossRef
8.
9.
Aparicio T, Zaanan A, Mary F, et al. Small bowel adenocarcinoma. Gastroenterol Clin North Am. 2016;45:447–57.CrossRef
10.
Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4:1–5.CrossRef
11.
Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.CrossRef
12.
Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101:2826–32.CrossRef
13.
Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRef
14.
Takayoshi K, Kusaba H, Uenomachi M, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRef
15.
Howe JR, Karnell LH, Menck HR, et al. Adenocarcinoma of the small bowel: review of the National Cancer Data Base. Cancer 1985-1995;86:2693–2706.
16.
Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199:797–803.CrossRef
17.
Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518–26.CrossRef
18.
Umman P, Adiyodi V, Narayan C. Small bowel adenocarcinoma—report of two cases and review of literature. Indian J Surg. 2013;75:123–7.CrossRef
19.
Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRef
20.
Schwameis K, Schoppmann SF, Stift J, et al. Small bowel adenocarcinoma—terra incognita: a demand for cross-national pooling of data. Oncol Lett. 2014;7:1613–7.CrossRef
21.
Lech G, Korcz W, Kowalczyk E, et al. Primary small bowel adenocarcinoma: current view on clinical features, prognostic factors, treatment and outcome. Scand J Gastroenterol. 2017;52:1194–202.CrossRef
22.
Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–603.CrossRef
23.
Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23:561–6.CrossRef
24.
25.
Kotoe T, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRef
26.
Gulhati P, Raghav K, Shroff R, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist. 2018;23:277e26.CrossRef
27.
Otsuji E, Yamaguchi T, Sawai K, et al. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol. 1998;67:216–20.CrossRef
28.
Makino T, Mishima H, Ikenaga M, et al. Clinicopathologic features of signet-ring cell carcinoma of the colon and rectum. Jpn J Gastroenterol Surg. 2006;39:16–22.CrossRef
29.
Liu An-Chieh, Chen Ch, et al. A rare Krukenberg tumor arising from a primary adenocarcinoma of the small intestine. Taiwan J Obstet Gynecol. 2018;57(2):319–22.CrossRef
30.
Woodruff JD, Novak ER. The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol. 1960;15:351–60.
31.
Mitsushita J, Tanaka A, et al. Metastatic ovarian tumors originating from a small bowel adenocarcinoma–a case report and brief literature review. Int J Gynecol Pathol. 2017;36(3):253–60.CrossRef
32.
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.CrossRef
33.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5).
34.
Shahabi V, Postow MA, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38(1):90–7.CrossRef
35.
Seyedin SN, Schoenhals JE, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967–80.CrossRef
36.
Hecht MI, Büttner-Herold M, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.CrossRef
37.
De Wolf K, Kruse V, et al. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;31;15(1):21.
38.
Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.CrossRef
39.
Kim ST, Cristescu R, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.CrossRef
Metadata
Title
A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control
Authors
Kazutaka Iijima
Mitsuharu Oozeki
Kaori Ikeda
Hiroyuki Honda
Hajime Ishibashi
Masaharu Yamaoka
Shinji Fujieda
Hitoaki Saitoh
Mitsuhide Goto
Masahiro Araki
Kenji Amagai
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 3/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01064-9

Other articles of this Issue 3/2020

Clinical Journal of Gastroenterology 3/2020 Go to the issue

Case Report

Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis

Case Report

Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report

Case Report

Distribution of lanthanum carbonate in the gastric mucosa confirmed by electron microscopy with a magnified endoscopy: a case report and literature review

Case Report

Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab

Case Report

Bone metastasis as a recurrence of early papillary adenocarcinoma of the stomach

Case Report

Pill-induced esophagitis caused by ingesting excessive caffeine tablets
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits